Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders
Open Access
- 27 November 2000
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 14 (11), 1495-1502
- https://doi.org/10.1046/j.1365-2036.2000.00835.x
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- The effect of omeprazole on intragastric pH and gastrin levels is determined by the CYP2C19 polymorphism more than by H. pylori infection in patients with acid related diseaseGastroenterology, 1998
- CYP2C19 genotype status and effect of omeprazole on intragastric pHGastroenterology, 1998
- CYP2C19 Genotype and Phenotype Determined with Omeprazole in Patients with Acid-Related Disorders with and withoutHelicobacter pyloriInfectionScandinavian Journal of Gastroenterology, 1998
- OmeprazoleDrugs, 1994
- Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: development of a specific radioimmunoassay for chromogranin A and its fragmentsJournal of Endocrinology, 1993
- Chromogranin a and Pancreastatin-Like Immunoreactivity in Serum of Gastrinoma PatientsActa Oncologica, 1993
- Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjectsPharmacogenetics, 1992
- Gastric histology and plasma gastrin response to a meal in patients with duodenal ulcer disease after five years treatment with ranitidineAlimentary Pharmacology & Therapeutics, 1990
- Long-Term Omeprazole Treatment in Man: Effects on Gastric Endocrine Cell PopulationsDigestion, 1988
- Enterochromaffin-Like Cell Carcinoids of Gastric Mucosa in Rats after Life-Long Inhibition of Gastric SecretionDigestion, 1986